The $8 billion punitive damages verdict Johnson & Johnson was ordered to pay a user of the company’s Risperdal drug in a Philadelphia courtroom earlier this month could be a harbinger of jurors’ growing hostility toward drug companies, legal experts said.

The Risperdal verdict, which is expected to be reduced, is just one of a steady stream of breathtaking verdicts Johnson & Johnson has faced in litigation over the safety of its products. The number of verdicts has some lawyers saying it may be time for Johnson & Johnson to reconsider its scorched earth tactic of fighting all lawsuits.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]